FDA warns of cardiac risk with stress test agents

FDA warns of cardiac risk with stress test agents

(HealthDay)—The use of cardiac nuclear stress test agents comes with a rare but serious risk of heart attack and death, according to a warning sent by the U.S. Food and Drug Administration to health care professionals.

Lexiscan (regadenoson) and Adenoscan (adenosine), used in cardiac stress tests in patients who cannot exercise adequately, help identify coronary artery disease by dilating heart arteries and increasing blood flow. The risk stems from reduced blood flow to obstructed areas, which may result in potentially fatal .

The FDA has approved drug label changes for the two drugs to highlight these risks and update recommendations for their use. At this time, it is not clear if there is any difference in risk between Lexiscan and Adenoscan.

According to the agency, should "screen all candidates for their suitability to receive Lexiscan or Adenoscan. Avoid using these drugs in patients with signs or symptoms of unstable angina or cardiovascular instability, as these patients may be at greater risk for serious cardiovascular adverse reactions."

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Beating the clock for ischemic stroke sufferers

7 hours ago

A ground-breaking computer technology raises hope for people struck by ischemic stroke, which is a very common kind of stroke accounting for over 80 per cent of overall stroke cases. Developed by research experts at The Hong ...

Risk for nonelective thoracic aortic sx up for uninsured

22 hours ago

(HealthDay)—Uninsured patients have an increased risk of nonelective thoracic aortic operations, and have increased risks of major morbidity or mortality, according to a study published online April 8 in ...

User comments